Cellectar Biosciences Inc (NASDAQ: CLRB) is setting up to have a strong week in the market this week after the company reported top-line data from a key clinical trial. Of course, the data proved to be overwhelmingly positive. Here’s what we saw from the CLRB press release…
CLRB Reports Updated Clinical Data
As mentioned above, Cellectar Biosciences is setting up to have a strong week in the market this week after the company announced that the ongoing median survival data surrounding Cohort 1 of a Phase 1 clinical trial. The clinical trial is designed to assess the company’s lead PDCTM compound known as CLR 131. According to the data released, patients involved in the study that are being treated for multiple myeloma have reached a median overall survival rate of 26.2 months. This mOS data is overwhelmingly positive, as the three most recently FDA-approved third-line therapies for the treatment of multiple myeloma demonstrate median overall survival that ranges from 11.9 to 18.6 months. It’s also worth mentioning that this number is likely to continue growing, as the study is ongoing.
In the first cohort of the study, heavily pretreated patients that have had an average of 5.8 prior lines of therapy were provided with a single 30-minute infusion of 12.5mCi/m2. These patients have been followed since receiving the treatment. The second and third cohorts are also generating positive news according to CLRB. These patients received a single dose of CLR 131 of 18.75 mCi/m2 and 25 mCi/m2 respectively and, to date, the patients have experienced an mOS of 15.4 months and 10 months respectively. Once again, all 3 cohorts of the trial are ongoing, and CLRB is expected to report an increase in mOS across all 3 cohorts moving forward.
CLRB also reminded investors that Cohorts 2 and 3 were initiated approximately 10 and 18 months after the initiation of Cohort 1. This period accounts for the difference in mOS between the cohorts. While all cohorts are still ongoing, the mOS in each cohort to date already compares favorably with the historic survival benefit associated with chemotherapy in relapsed/refractory multiple myeloma. In a statement, Jim Caruso, President and CEO at CLRB, offered the following:
“The ongoing median overall survival from the first cohort exceeding two years, and the second cohort’s mOS surpassing 15 months underscore the clinical potential of our CLR 131 program in multiple myeloma… These observations taken together with the recently reported partial response from Cohort 3 leave us very optimistic with regard to advancing this compound through the clinic.”
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on CLRB. In particular we’re interested in following the ongoing study surrounding CLR 131 as well as the ongoing work the company is doing with regard to the rest of its robust clinical pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!